MKI67 and neoplasm: Further characterization of the CD109-silenced MES-like xenografts revealed a significant reduction in the number of Ki-67–positive proliferating tumor cells and OLIG2-positive GSCs (Figure 5, O–R; and Supplemental Figure 5, F–I).